Trump administration reclassifies medical marijuana from Schedule I to Schedule III
DOJ move covers FDA-approved and state-licensed medical marijuana, easing research barriers but not federally legalising the drug
Briefing
- The Trump administration has reclassified state-licensed and FDA-approved medical marijuana from Schedule I to the less strictly regulated Schedule III under federal law.
- The reclassification is described as a historic shift in US federal cannabis policy, the most significant change in decades.
- The move eases barriers to scientific research on cannabis but does not federally legalise marijuana or alter current federal criminal penalties.
- Action follows a Trump executive order issued in January instructing agencies to move toward easing marijuana controls.
- The reclassification applies specifically to state-licensed medical marijuana, not to cannabis broadly.
Analysis
- Reclassification to Schedule III removes the 280E tax burden that has been the primary structural drag on US multi-state operator profitability. CURLF, TCNNF, CRLBF, and GTBIF would see immediate improvement in after-tax cash flow without any change in top-line revenue, since 280E disallows standard business deductions for Schedule I and II cannabis businesses. This is not legalization, so banking access and interstate commerce restrictions remain, but the tax relief alone materially alters the earnings profile of MSOs operating in states with large taxable income.
- Canadian licensed producers CGC and TLRY benefit less directly than US MSOs: their primary exposure is US market access and sentiment re-rating rather than 280E relief, which applies only to US taxpayers. Reclassification does not open US import channels for Canadian product, so the near-term fundamental catalyst for CGC and TLRY is speculative re-rating on legalization optionality rather than any concrete operational improvement. This creates a divergence in quality of catalyst between US MSOs and Canadian producers that the market may initially obscure in a broad sector rally.
- Schedule III reclassification accelerates institutional due diligence on cannabis sector financing, since federal banking regulators have historically cited Schedule I status as a basis for discouraging cannabis-related accounts. While the SAFE Banking Act has not passed, reclassification reduces the regulatory risk premium that has kept major commercial banks out of direct cannabis lending. Regional banks with existing cannabis-adjacent exposure and specialty lenders are most immediately positioned to expand credit availability to MSOs, compressing the cost of capital that has constrained sector consolidation.
Historical Context
- 2024
The Biden-era DEA proposed moving marijuana to Schedule III following an HHS recommendation, but the process stalled in administrative review. That proposal established the legal and procedural pathway the Trump administration is now accelerating, making DOJ action a continuation of an existing rulemaking record rather than a new initiation.
- 2012-2014
Colorado and Washington state legalization created the first state-legal cannabis markets under continued federal Schedule I status, establishing that state-level markets can scale substantially without federal reclassification. This precedent bounds the upside from Schedule III reclassification: operational scale is already proven; the incremental gain is tax treatment and institutional capital access, not market existence.
- 1970
The Controlled Substances Act placed marijuana in Schedule I, triggering the 280E tax provision that prohibits cannabis businesses from deducting ordinary business expenses. Every dollar of 280E relief from reclassification directly converts to after-tax income for US operators, a mechanical relationship established by IRS code and confirmed in multiple Tax Court rulings.
Connected Events
Further reading
See Indexa more often on Google
Mark Indexa as a preferred source — your Top Stories will surface more Indexa coverage.
